ENV-308 / Enveda Biosci - LARVOL DELTA

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy (Businesswire) - "The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and early pharmacodynamic signals of ENV-308."

IND • Trial status • Obesity